Clinical Trial Update: Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating nivolumab in combination with metformin for metastatic renal cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• metformin (metformin)
• nivolumab (nivolumab)

Snippet

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: TERMINATED